|drug3322||Symptom Survey Wiki||1.00|
|drug3674||Vitamin C Wiki||0.28|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
In December 2019, a new type of pneumonia, COVID-2019 outbroke in Wuhan ,China, and currently the infected has been reported in more than at least 75 countries. Patients with severe COVID-19 have rapid disease progression and high mortality rate. This may attribute to the excessive immune response caused by cytokine storm. Strategies based on anti-virus drugs and treatments against symptoms have now been employed. However, these managements can't effectively treat the lethal lung injury and uncontrolled immune responses, especially in the elderly with severe COVID-19. Traditional Chinese Medicine (TCM), which treats the disease from anther perspective, has achieved satisfactory results. National Health Commission of China released a series of policies to enhance the administration of TCM prescriptions. This study is aimed to evaluate the efficacy and safety of Traditional Chinese Medicine as an adjuvant treatment for severe COVID-19.
Description: The pneumonia severity index is a clinical tool helping in the risk stratification of patients with community-acquired pneumonia. It ranges from 0-395 scores and a higher score indicates higher death risk.Measure: The pneumonia severity index scores Time: First treatment date up to 3 months
Description: Changes in leukocyte, neutral, lymphocyte counts and absolute lymphocyte count from baselineMeasure: Blood immune cell count Time: Baseline, 7 and/ or 14 days
Description: Changes in blood interleukin-6, c-reactive protein,SS-A/Ro antibodies and serum ferritin from baseline.Measure: Serum inflammatory markers Time: Baseline, 7 and/ or 14 days
Description: Changes in erythrocyte sedimentation rate from baseline.Measure: Erythrocyte sedimentation rate Time: Baseline, 7 and/ or 14 days
Description: Changes in platelets and D-dimers from baseline.Measure: Platelet and D-dimer changes Time: Baseline, 7 and/ or 14 days
Description: Changes in serum creatinine from baseline.Measure: Creatinine changes Time: Baseline, 7 and/ or 14 days
Description: Changes in serum muscle enzymes from baseline, including alanine aminotransferase , AST, creatine kinase, LDH.Measure: Muscle enzymes changes Time: Baseline, 7 and/ or 14 days
Description: Dosing time and amounts of antibiotics；the categories of the antibioticsMeasure: Usage of antibiotics Time: First treatment date up to 3 months
Description: Dosing time and amounts of glucocorticoidsMeasure: Usage of glucocorticoids Time: First treatment date up to 3 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports